Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals With Functional Impairment Related to Mood, Anxiety, Trauma and/or Addiction Symptoms: An Open-label Proof-of-concept Study

NCT06442423 is registered in ClinicalTrials.gov with Yale University as lead sponsor.

NCT NCT06442423
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06442423 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals With Functional Impairment Related to Mood, Anxiety, Trauma and/or Addiction Symptoms: An Open-label Proof-of-concept Study
Lead sponsor
Yale University
Phase
Phase 1
Overall status
Recruiting
Start date
October 17, 2024
Completion date
December 31, 2027
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anxiety, depression - major depressive disorder, ocd, ptsd, ptsd symptoms, substance use, substance use disorder (sud), transdiagnostic